Jeddah

Futó vizsgálatok

• Toboroz

  CHARM Hepatocellular Carcinoma MEA Study

  NCT07650773· Forrás

• Toboroz

  BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy

  NCT07597993· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· Forrás

• Toboroz

  A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region

  NCT07065344· Forrás

• Toboroz

  INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

  NCT06314282· Forrás

• Toboroz

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· 3. fázis· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· Forrás

• Fut, nem toboroz

  Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

  NCT05301842· 3. fázis· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· 3. fázis· Forrás

• Fut, nem toboroz

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

  NCT03836261· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok2 toboroz
• Máj- és epeúti rák2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Áttétes emlőrák1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Elhízás1 toboroz
• Szívelégtelenség1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

  NCT05603845· Forrás

• Lezárult

  A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

  NCT06039683· Forrás